MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
36.4 M |
Market Cap[1] |
$ 1.45 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.32 | 4.36 % | $ 1.82 B | Nasdaq Global Select Market,SPB | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 11.1 | 2.59 % | $ 237 K | Nasdaq Global Select Market,SPB | USA |
 |
Exelixis
EXEL
|
$ 62.23 | 0.06 % | $ 16.9 B | Nasdaq Global Select Market,SPB | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
$ 2.99 | 4.32 % | $ 219 K | Nasdaq Global Market | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.17 | 1.53 % | $ 275 K | NYSE American | USA |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | USA |
 |
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market |  Irlanda |
 |
Akebia Therapeutics
AKBA
|
$ 0.67 | 0.14 % | $ 172 M | Nasdaq Global Market | USA |
 |
GlaxoSmithKline plc
GSK
|
$ 49.51 | 1.0 % | $ 201 B | NYSE |  Britain |
 |
GT Biopharma
GTBP
|
$ 7.03 | 18.52 % | $ 38.8 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.36 | 4.01 % | $ 60 M | Nasdaq Global Select Market,SPB | USA |
 |
Johnson & Johnson
JNJ
|
$ 255.56 | 0.86 % | $ 615 B | NYSE,SPB | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.18 | 19.02 % | $ 551 B | Nasdaq Capital Market | Britain |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 28.82 | 10.19 % | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.7 | 0.62 % | $ 42 M | Nasdaq Global Select Market | USA |
 |
Kura Oncology
KURA
|
$ 9.08 | 0.94 % | $ 796 M | Nasdaq Global Select Market | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Kaleido Biosciences
KLDO
|
- | -3.69 % | $ 12.4 M | Nasdaq Global Select Market | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | Nasdaq Global Select Market | USA |
 |
Alector
ALEC
|
$ 1.84 | 6.02 % | $ 190 M | Nasdaq Global Select Market,SPB | USA |
 |
ObsEva SA
OBSV
|
- | -15.52 % | $ 10.5 M | Nasdaq Global Select Market |  Schweiz |
 |
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | USA |
 |
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | Nasdaq Global Market | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
- | 7.4 % | $ 6.29 M | Nasdaq Global Market | USA |
 |
Provention Bio
PRVB
|
- | - | $ 2.37 B | Nasdaq Global Select Market | USA |
 |
Poseida Therapeutics
PSTX
|
- | - | $ 857 M | Nasdaq Global Select Market | USA |
 |
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | USA |
 |
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | USA |
 |
Virpax Pharmaceuticals
VRPX
|
- | -45.12 % | $ 2.85 M | Nasdaq Global Select Market | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.06 | 6.0 % | $ 56.9 M | Nasdaq Global Select Market,SPB | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | 0.09 % | $ 226 M | NYSE American | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
- | - | $ 23.9 M | Nasdaq Global Select Market | USA |
 |
Satsuma Pharmaceuticals
STSA
|
- | -0.9 % | $ 36.5 M | Nasdaq Global Market | USA |
 |
SpringWorks Therapeutics
SWTX
|
- | - | $ 3.48 B | Nasdaq Global Select Market,SPB | USA |
 |
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | USA |
 |
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | USA |
 |
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market | USA |
 |
Y-mAbs Therapeutics
YMAB
|
- | - | $ 382 M | Nasdaq Global Select Market,SPB | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
- | -2.99 % | $ 2.47 M | NYSE American | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BELLUS Health
BLU
|
- | - | $ 2.47 B | Nasdaq Global Select Market |  Canada |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Intra-Cellular Therapies
ITCI
|
- | - | $ 13.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | USA |
 |
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.